Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F

被引:8
作者
Kim, MJ
Park, KG
Lee, KM
Kim, HS
Kim, SY
Kim, CS
Lee, SL
Chang, YC
Park, JY
Lee, KU
Lee, IK
机构
[1] Keimyung Univ, Sch Med, Dept Internal Med, Taegu 700712, South Korea
[2] Keimyung Univ, Sch Med, Inst Med Sci, Dept Physiol, Taegu 700712, South Korea
[3] Keimyung Univ, Sch Med, Dept Pediat, Taegu 700712, South Korea
[4] Catholic Univ Daegu, Sch Med, Dept Pathol, Taegu, South Korea
[5] Univ Ulsan, Coll Med, Dept Internal Med, Seoul, South Korea
关键词
diabetes mellitus; hyperplasia; vascular smooth muscle cells;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 [临床医学]; 100210 [外科学];
摘要
Neointimal formation, the leading cause of restenosis, is caused by proliferation of vascular smooth muscle cells (VSMCs). Patients with diabetes mellitus have higher restenosis rates after coronary angioplasty than nondiabetic patients. Cilostazol, a selective type 3 phosphodiesterase inhibitor, is currently used to treat patients with diabetic vascular complications. Cilostazol is a potent antiplatelet agent that inhibits VSMC proliferation. In the present study, we examine whether the antiproliferative effect of cilostazol on VSMCs is mediated by inhibition of an important cell cycle transcription factor, E2F. Cilostazol inhibited the proliferation of human VSMCs in response to high glucose in vitro and virtually abolished neointimal formation in rats subjected to carotid artery injury in vivo. Moreover, the compound suppressed high-glucose-induced E2F-DNA binding activity, and the expression of E2F1, E2F2, cyclin A, and PCNA proteins. These data suggest that the beneficial effects of cilostazol on high-glucose-stimulated proliferation of VSMCs are mediated by the downregulation of E2F activity and expression of its downstream target genes, including E2F1, E2F2, cyclin A, and PCNA.
引用
收藏
页码:552 / 556
页数:5
相关论文
共 41 条
[1]
Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia [J].
Ahn, JD ;
Morishita, R ;
Kaneda, Y ;
Kim, HS ;
Chang, YC ;
Lee, KU ;
Park, JY ;
Lee, HW ;
Kim, YH ;
Lee, IK .
GENE THERAPY, 2002, 9 (24) :1682-1692
[2]
E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells [J].
Ahn, JD ;
Kim, CH ;
Magae, J ;
Kim, YH ;
Kim, HJ ;
Park, KK ;
Hong, SH ;
Park, KG ;
Lee, IK ;
Chang, YC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 310 (04) :1048-1053
[3]
[Anonymous], DIABETES
[4]
BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33
[5]
Regulation of E2F: a family of transcription factors involved in proliferation control [J].
Black, AR ;
Azizkhan-Clifford, J .
GENE, 1999, 237 (02) :281-302
[6]
Rapamycin inhibits E2F-dependent expression of minichromosome maintenance proteins in vascular smooth muscle cells [J].
Bruemmer, D ;
Yin, F ;
Liu, J ;
Kiyono, T ;
Fleck, E ;
Van Herle, AJ ;
Law, RE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 303 (01) :251-258
[7]
Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene [J].
Chang, YC ;
Illenye, S ;
Heintz, NH .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (04) :1121-1131
[8]
RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY - HAVE WE BEEN AIMING AT THE WRONG TARGET [J].
CURRIER, JW ;
FAXON, DP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (02) :516-520
[9]
CELL-CYCLE REGULATION OF THE HUMAN CDC2 GENE [J].
DALTON, S .
EMBO JOURNAL, 1992, 11 (05) :1797-1804
[10]
Cilostazol has beneficial effects in treatment of intermittent claudication - Results from a multicenter, randomized, prospective, double-blind trial [J].
Dawson, DL ;
Cutler, BS ;
Meissner, MH ;
Strandness, DE .
CIRCULATION, 1998, 98 (07) :678-686